Exhibit 99.2
PRIVATE AND CONFIDENTIAL
The Board of Directors
Actavis, Inc.
Morris Corporate Center III
400 Interpace Parkway
Parsippany, NJ 07054
Members of the Board:
30 July 2013
We hereby consent to the inclusion of our opinion letter, dated May 19, 2013, to the Board of Directors of Actavis, Inc. (“Actavis”) as Annex E to, and to the reference thereto under the headings “SUMMARY—Opinions of Actavis’ Financial Advisors,” “THE TRANSACTION— Recommendation of the Actavis Board of Directors and Actavis’ Reasons for the Transaction” and “THE TRANSACTION—Opinions of Actavis’ Financial Advisors” in, the joint proxy statement/prospectus relating to the proposed transaction involving Actavis, Actavis Limited (“New Actavis”) and Warner Chilcott plc, which joint proxy statement/prospectus forms a part of New Actavis’ Amendment No. 1 to the Registration Statement on Form S-4 to which this consent is filed as an exhibit.
In giving the foregoing consent, we do not admit (1) that we come within the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended (the “Securities Act”), or the rules and regulations of the Securities and Exchange Commission (the “Commission”) promulgated thereunder, or (2) that we are experts with respect to any part of the Registration Statement within the meaning of the term “experts” as used in the Securities Act and the rules and regulations of the Commission promulgated thereunder.
Yours faithfully,
for and on behalf of Merrill Lynch, Pierce, Fenner & Smith Incorporated
/s/ Chris Seiter
Chris Seiter
Merrill Lynch, Pierce, Fenner & Smith Incorporated
One Bryant Park,
New York,
NY 10036
USA
